Waters Corp
WAT
Market cap $20.4B

342.63 USD

+3.27

0.96%

At close Jun 20, 4:00 PM EDT

After hours

342.63

+0.00

0.00%

1 day

0.96%

5 days

-0.29%

1 month

-5.38%

3 months

-5.67%

6 months

-6.93%

Year to date

-6.96%

1 year

18.15%

5 years

84.66%

10 years

151.27%

About: Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions.

Employees: 7,600

Healthcare Diagnostics & Research

0

Funds holding %

of 7,302 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

185% more call options, than puts

Call options by funds: $33.4M | Put options by funds: $11.7M

33% more funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 8 (+2) [Q1 2025]

23% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 62

6% more repeat investments, than reductions

Existing positions increased: 276 | Existing positions reduced: 261

0% less funds holding

Funds holding: 745 [Q4 2024] → 744 (-1) [Q1 2025]

0.63% less ownership

Funds ownership: 95.91% [Q4 2024] → 95.28% (-0.63%) [Q1 2025]

1% less capital invested

Capital invested by funds: $21.1B [Q4 2024] → $20.8B (-$285M) [Q1 2025]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$350

2%

upside

Avg. target

$386

13%

upside

High target

$460

34%

upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

Baird Catherine Ramsey	9%upside $374	Outperform Maintained	7 May 2025
UBS Elizabeth Garcia	5%upside $360	Neutral Maintained	7 May 2025
Barclays Luke Sergott	2%upside $350	Equal-Weight Maintained	10 Apr 2025
Keybanc Paul Knight	34%upside $460	Overweight Upgraded	31 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about WAT published over the past 30 days

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity

News Summary Industry-first smart HPLC system to provide authenticated user access verification on onboard touchscreen for superior security. Integration of Alliance™ iS HPLC System with Empower™ Software ensures user actions are identifiable and auditable.

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity

Zacks Investment Research

Here's Why Waters (WAT) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Waters (WAT) is a Strong Growth Stock

Zacks Investment Research

Waters (WAT) Up 2.2% Since Last Earnings Report: Can It Continue?

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Waters (WAT) Up 2.2% Since Last Earnings Report: Can It Continue?

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass.

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

Zacks Investment Research

Why Waters (WAT) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Waters (WAT) is a Top Growth Stock for the Long-Term

Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality

News Summary Enables measurements up to 2 days earlier for antibody titers for both clone selection and bioprocess monitoring.1 Provides up to 7x improvements in sensitivity with novel high efficiency particles.2 Delivers 2x more attribute information with simplified multi-attribute workflows.3 MILFORD, Mass. , May 28, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements.

Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality

Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

MILFORD, Mass. , May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies.

Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

Waters Corporation to Present at the Jefferies Global Healthcare Conference

MILFORD, Mass. , May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

Waters Corporation to Present at the Jefferies Global Healthcare Conference

Waters Corp's India business boosted by rush for weight-loss drugs

U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers in India rushing to develop their versions of popular weight-loss drugs, a senior executive told Reuters.

Waters Corp's India business boosted by rush for weight-loss drugs

Zacks Investment Research

Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y

WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.

Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y

See News Rankings

Charts implemented using Lightweight Charts™